Abstract library

425 results for "selective arterial secretagogue injection test".
#1074 Usefulness of a Combination of a 48-Hour Fasting and a Glucagon Tolerance Test
Introduction: The 72-hour fasting test is the gold standard for the diagnosis of insulinoma. However, the test can become a burden for both patients and medical staff and, shortening the duration of fast has been attempted. There are several reports on the high sensitivity of fasting test but only a few reports on its specificity. An insulinoma can be localized using invasive tests such as endoscopic ultrasonography and selective arterial secretagogue injection test. Therefore, insulinoma detection with high specificity may be needed to avoid unnecessary examinations.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Keijiro Ueda
Authors: Ueda K, Lee L, Hijioka M, Igarashi H, ...
#1699 Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 Seconds or At 120 Seconds?
Introduction: The selective arterial secretagogue injection (SASI) test is considered indispensable for an accurate insulinoma localization. The optimal timing of post-injection evaluation has not been established yet, as some studies recommend 60 seconds [SASI (60 sec)] while others support 120 seconds [SASI (120 sec)].
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Keijiro Ueda
Authors: Ueda K, Kawabe K, Lee L, Tachibana Y, ...
#1464 A Case of Multiple Pancreatic Insulinoma Laparoscopically Resected through Precise Spatial Diagnosis by SACI Test
Introduction: Case: A 58-year-old man representing cold sweat, palpitation and nausea was admitted to our hospital and was pointed out parathyroid, pancreatic and superior mediastinal masses with CT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Sato A, Ito T, ...
#695 Pancreatic Angiography with Selective Intra-Arterial Calcium Stimulation for the Localization of Insulinomas: A Case Report.
Introduction: Surgery is the gold standard treatment of insulinomas. Before planning the surgical procedure, the tumor must be precisely localized. Usually, the combination of Endoscopic Ultrasound, Computed Tomography and Magnetic Resonance Imaging localize more than 80% of the tumors. But due to its small size, other more sophisticated techniques must be performed in order to improve the diagnosis accuracy. Some of them, like angiography, are invasive.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Medical Doctor Javier Pi
#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#1378 Evaluation of CT Prognostic Factors of Neuroendocrine Liver Metastasis Treated with Transcatheter Arterial Embolization
Introduction: TAE has been shown to be effective in the management of metastatic NET.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Liu P, Cao K, Li J, ...
#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Hannah Kurth
Authors: Adelman D, Burgess A, Davies P R, ...
#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Conference:
Category: Basic
Presenting Author: Dr Roberta Elisa Rossi
#686 Hepatic Arterial Embolization for Gastroenteropancreatic NET Liver Metastases
Introduction: Selective hepatic arterial embolization (HAE) with polyvinyl alcohol particles has been shown to be equivalent to chemoembolization for patients with hepatic gastroenteropancreatic (GEP) neuroendocrine metastases. There remains debate about its clinical effectiveness and which patients benefit from treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Mr Colin Wilson
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.